Short rna antagonist compounds for the modulation of hif-1alpha
OwnerMaj HEDTJÄRN, Jens Bo Rode Hanseninventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to oligomeric compounds (oligomers) of 12, 13 or 14 nucleotides in length, which target Hif-1alpha mRNA in a cell, leading to reduced expression of Hif-1alpha. Reduction of Hif-1alpha expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative disorders, such as cancer.
Claims18
An oligonucleotide compound consisting of 12 to 16 contiguous monomers,
- wherein adjacent monomers are covalently linked by a phosphate group or a phosphorothioate group,
- wherein said oligomer comprises a first region of 12 contiguous monomers;
- wherein at least one monomer of said first region is a nucleoside analogue;
- and
- wherein the sequence of said first region is 5′GCAAGCATCCTG-3′ (SEQ ID NO:
- 5).
A method of inhibiting the expression of Hif-1alpha in a cell, comprising contacting said cell with an effective amount of an oligomer consisting of 12 to 16 contiguous monomers,
- wherein adjacent monomers are covalently linked by a phosphate group or a phosphorothioate group,
- wherein said oligomer comprises a first region of 12 contiguous monomers;
- wherein at least one monomer of said first region is a nucleoside analogue;
- and
- wherein the sequence of said first region is 5′-GCAAGCATCCTG-3′ (SEQ II) NO:
- 5).
A method of inhibiting the expression of Hif-1alpha in a tissue of a mammal, comprising contacting said tissue with an effective amount of an oligomer consisting of 12 to 16 contiguous monomers,
- wherein adjacent monomers are covalently linked by a phosphate group or a phosphorothioate group,
- wherein said oligomer comprises a first region of 12 contiguous monomers;
- wherein at least one monomer of said first region is a nucleoside analogue;
- and
- wherein the sequence of said first region is 5′-GCAAGCATCCTG-3′ (SEQ ID NO:
- 5).
Dependencies are inferred from the claim text.